Adropin, a recently described peptide hormone produced in brain and liver, has 29 been reported to have physiologically relevant actions on glucose homeostasis and 30 lipogenesis, and to exert significant effect on endothelial function. We describe a 31 central nervous system action of adropin to inhibit water drinking and identify a 32 potential adropin receptor, the orphan G protein-coupled receptor, GPR19. 33
2 production. The authors went further to show that transgenic overexpression of 47 adropin and pharmacologic administration of the peptide improved insulin 48 sensitivity in mice exposed to a high fat diet (the diet induced obesity model, or 49 DIO). These effects were reported to be independent of changes in food intake, 50 energy expenditure or body weight. Indeed there were no reported differences in 51 food intake in transgenic overexpressing mice compared to controls; however, in 52 DIO B6 mice adropin administration (i.p. twice daily for 14 days) significantly 53 reduced food intake compared to controls. Another important observation in the 54 transgenic mice was that the expression of genes involved in lipid synthesis was 55 decreased suggesting, when considered along side the evidence that the onset of 56 diet induced obesity in these animals was delayed, that adropin not only improves 57 glucose homeostasis, but also protects against over accumulation of lipid during 58 high fat diet exposure. The same group then reported in 2012 (7) that adropin 59 deficiency resulted in the opposite phenotype: increased adiposity and insulin 60 resistance. The authors concluded that adropin deficiency could predispose 61 individuals to the development of diabetes (T2DM) and the Metabolic Syndrome. 62 63
Shortly after the first publication on adropin (6), Lovren injected controls all three adropin groups consumed significantly less water at 1800 208 h and animals in the 2.0 nanomole group had consumed significantly less water than 209 controls also at 1830 and 1900 h (Figure 1 a) . Food intakes were not significantly 210 different among groups, with the exception of a difference between vehicle and 2.0 211 nanomole administered animals at 1900 h (Figure 1b) . No significant differences in 212 water or food intakes were detected at 1930 h or the following morning at 0800 h. 213 214 Protocol 2. Significantly less water was consumed by 3.0 nanomole adropin treated 215 rats than vehicle treated controls following overnight water restriction at all times 216 (Figure 2 ) except immediately following return of water bottles to the cages (15 217 minutes). Again, no significant differences in cumulative water intakes among the 218 adropin treatment groups were observed. At 0800 h on the following morning, no 219 significant differences were observed in cumulative water intakes among the groups 220 (vehicle controls: 37.7 ± 2.1; 1.0 nanomole: 35.5 ± 3.7; 3.0 nanomoles: 38.1 ± 3.8 ml 221 water). 222 223 Protocol 3. No significant differences in 24 hour, ad libitum water intakes were 224 observed between the two treatment groups prior to overnight water restriction 225 either before or during the period of siRNA treatment. Rats pretreated for two 226 consecutive days with siRNA targeting GPR19 consumed significantly more water 227 following i.c.v. adropin administration than rats pretreated with the control siRNA 228 (Figure 3 ). Significant differences in cumulative water intakes were observed at all 229 time points, with more water consumed by the GPR19 siRNA pretreated animals. The broad distribution of adropin production in brain (6) suggested to us a central 248 nervous system site of action. The action of peripherally administered adropin to 249 alter food intake in DIO B6 mice (7) (KATO III), human coronary artery endothelial cells (HCAEC) and mouse fibroblasts 272 (3T3-L1)] using cfos mRNA expression as a reporter of cellular activation. We then 273 generated an orphan GPCR expression profile, using PCR, to identify shared 274 populations of orphan receptors and in doing so identified five potential candidates; 275 GPR151, TAAR9, GPR160, GPR19 and GPR63. Based on expression patterns in the 276 published literature (5,9) and in vitro receptor compromise work still ongoing in 277 the laboratory we identified GPR19 to be our best candidate receptor. We 278 hypothesized that compromise of GPR19 expression would abrogate the action of 279 adropin to inhibit water deprivation-induced drinking. 280 281
We developed with the assistance of IDT a triple cocktail of siRNA with which we 282 could reduce GPR19 mRNA levels in cultured cells and turned to our in vivo model 283 of adropin's CNS action, the inhibition of water deprivation-induced water drinking, 284 to study the potential physiologic relevance of adropin production in brain. 285
Administration of GPR19 siRNA i.c.v. for two days significantly lowered receptor 286 mRNA levels in medial basal hypothalamus of male rats. The inhibitory action of 287 adropin on water deprivation-induced drinking behavior was prevented when 288 mRNA levels of GPR19 had been reduced significantly by pretreatment with siRNA 289 targeting the receptor. Thus we feel that we have identified a potential receptor for 290 adropin, a step necessary before the physiological relevance of the pharmacologic 291 effects of the peptide can be fully understood. 292 293
An important question when using in vivo siRNA is how much knockdown of the 294 target is required to observe significant effects. with MAP recorded every minute for thirty minutes post injection. 467
